Phase transitions in diluted negative-weight percolation models

We investigate the geometric properties of loops on two-dimensional lattice graphs, where edge weights are drawn from a distribution that allows for positive and negative weights. We are interested in the appearance of spanning loops of total negative weight. The resulting percolation problem is fundamentally different from conventional percolation, as we have seen in a previous study of this model for the undiluted case. Here, we investigate how the percolation transition is affected by additional dilution. We consider two types of dilution: either a certain fraction of edges exhibit zero weight, or a fraction of edges is even absent. We study these systems numerically using exact combinatorial optimization techniques based on suitable transformations of the graphs and applying matching algorithms. We perform a finite-size scaling analysis to obtain the phase diagram and determine the critical properties of the phase boundary. We find that the first type of dilution does not change the universality class compared to the undiluted case whereas the second type of dilution leads to a change of the universality class.Comment: 8 pages, 7 figure

Analysis of the loop length distribution for the negative weight percolation problem in dimensions d=2 through 6

We consider the negative weight percolation (NWP) problem on hypercubic lattice graphs with fully periodic boundary conditions in all relevant dimensions from d=2 to the upper critical dimension d=6. The problem exhibits edge weights drawn from disorder distributions that allow for weights of either sign. We are interested in in the full ensemble of loops with negative weight, i.e. non-trivial (system spanning) loops as well as topologically trivial ("small") loops. The NWP phenomenon refers to the disorder driven proliferation of system spanning loops of total negative weight. While previous studies where focused on the latter loops, we here put under scrutiny the ensemble of small loops. Our aim is to characterize -using this extensive and exhaustive numerical study- the loop length distribution of the small loops right at and below the critical point of the hypercubic setups by means of two independent critical exponents. These can further be related to the results of previous finite-size scaling analyses carried out for the system spanning loops. For the numerical simulations we employed a mapping of the NWP model to a combinatorial optimization problem that can be solved exactly by using sophisticated matching algorithms. This allowed us to study here numerically exact very large systems with high statistics.Comment: 7 pages, 4 figures, 2 tables, paper summary available at http://www.papercore.org/Kajantie2000. arXiv admin note: substantial text overlap with arXiv:1003.1591, arXiv:1005.5637, arXiv:1107.174

Nonlinear Dynamics of Parity-Even Tricritical Gravity in Three and Four Dimensions

Recently proposed "multicritical" higher-derivative gravities in Anti de Sitter space carry logarithmic representations of the Anti de Sitter isometry group. While generically non-unitary already at the quadratic, free-theory level, in special cases these theories admit a unitary subspace. The simplest example of such behavior is "tricritical" gravity. In this paper, we extend the study of parity-even tricritical gravity in d = 3, 4 to the first nonlinear order. We show that the would-be unitary subspace suffers from a linearization instability and is absent in the full non-linear theory.Comment: 22 pages; v2: references added, published versio

Conformal field theories dual to quantum gravity with strongly coupled matter

A holographic conformal field theory is dual to semiclassical general relativity in anti–de Sitter space coupled to matter fields. If the conformal field theory (CFT) factorizes in the large-N limit, then all couplings in its dual are suppressed by the Planck scale, making the matter fields weakly interacting. We propose a mechanism to produce CFTs whose dual matter fields couple weakly to gravity, but interact strongly with each other. We achieve this by turning on exactly marginal multitrace deformations, and quantify the effect using conformal perturbation theory

Performance and Enhanced Efficiency Induced by Cold Plasma on SAPO-34 Membranes for CO\u3csub\u3e2\u3c/sub\u3e and CH\u3csub\u3e4\u3c/sub\u3e Mixtures

In this study, we investigate the influence of cold-plasma-induced enhanced performance and efficiency of SAPO-34 membranes in the separation of CO2 and CH4 mixtures. Placing the herein presented research in a broader context, we aim to address the question of whether cold plasma can significantly impact the membrane performance. We subjected SAPO-34 membranes to plasma mild disturbances and analyzed their performance in separating CO2 and CH4. Our findings reveal a notable enhancement in membrane efficiency and sustained performance when exposed to cold plasma. The pulsed plasma separation displayed improved structural integrity, and the experimental results indicated that the linear structure of CO2 facilitates the distortion of electron clouds in response to the electric field, a property known as polarizability, which aids in effective separation. Plausible mechanistic insight indicated that the intermolecular forces facilitated an integral role in SAPO-34 membranes exhibiting strong electrostatic interactions. In conclusion, our research highlights the potential of cold plasma as a promising technique for improving the performance of SAPO-34 membranes in gas mixtures at atmospheric pressures, providing valuable insights for optimizing membrane technology in carbon capture and gas separation applications

Supervised exercise with or without laser-guided feedback for people with non-specific chronic low back pain. A randomized controlled clinical trial

Background: Among the most effective therapeutic interventions in non-specific chronic low back pain (NSCLBP), clinical practice guidelines highlight exercise therapy and patient education; However, regarding the combined intervention of exercise and Pain Neuroscience Education (PNE), there is no consensus on the most effective form of exercise. Objetive: To find out what changes occurred after the application of two exercise modalities [Supervised Exercise (SE) and Laser-Guided Exercise (LGE)] and PNE on pain, pain pressure thresholds, disability, catastrophizing, kinesiophobia and lumbar proprioception in subjects with NSCLBP. Methods: Single-blind randomized clinical controlled trial. 60 subjects with NSCLBP. Both groups performed a a total of 16 therapeutic exercise sessions and 8 Pain Neuroscience Education sessions. With the Laser-Guided Exercise Therapy group performing laser-guided exercises. Results: A significant decrease was observed for pain intensity for both groups between baseline and post-intervention and the 3 month follow-up (p < 0.001). There was a significant between-group difference between baseline and post-intervention scores in terms of pain intensity and kinesiophobia in favour of the LGE group. Conclusion: Supervised exercise with or without laser feedback, when combined with PNE, reduces pain intensity, disability, pain catastrophizing, kinesiophobia and improves proprioception and PPTs in patients with NSCLBP. At a 3-month follow-up, the combination of LGE plus PNE is most effective for reducing pain intensity

Size and body condition drive the energetic cost of a baleen whale foraging in shallow habitat

Funding: Data collection was supported by the NOAA National Marine Fisheries Service Office of Science and Technology Ocean Acoustics Program [2016 and 2017; 50-27], the Oregon Sea Grant Program Development funds [2018; RECO-40-PD], the Oregon State University Marine Mammal Institute [2019], and the Office of Naval Research Marine Mammals and Biology program [2020-2022; #N00014-20-1-2760].Energy expenditure strongly influences an animal’s foraging decisions and activity budgets. Diving animals especially need to be energetically efficient because they exercise while oxygen is limited. By estimating the energetics of behavior, we can better understand the cascading effects of individual responses to disturbance and environmental change. Pacific Coast Feeding Group (PCFG) gray whales use a variety of foraging tactics in shallow habitats (<20 m), which present challenges associated with maneuverability and buoyancy. We use a seven-year dataset of concurrent individual behavior, morphology, and breath-by-breath respiration data collected via drone paired with two years of tri-axial accelerometry tag data to study patterns and correlates of respiration. We assess how several respiration metrics (acting as proxies for oxygen consumption) are associated with individual length, body condition and behavior (forage and travel), and test whether respiration reflects recovery from, or anticipation of, a foraging dive using Bayesian linear mixed effects models. Given model results, we simulated daily field metabolic rate (FMR) to explore how diving costs may affect energetics at a daily scale. We find that respiration reflects recovery from the preceding dive and that dives are more energetically expensive for longer, more buoyant whales. Longer dives and the most common foraging tactics also incur higher energetic costs. FMR simulations show that individual size and dive duration have the largest effects on energy expenditure. Thus, PCFG gray whale foraging success may be limited by the energetic costs associated with size and buoyancy, highlighting the costs of a shallow habitat foraging niche.Peer reviewe

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary objectives included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD-L1-associated clinical activity. PD-L1 positivity was defined as expression by immunohistochemistry on ≥ 5% of tumor cells. Results Forty-four patients were treated with avelumab and followed for a median of 16.5 months (interquartile range, 15.8 to 16.7 months). The data cutoff was March 19, 2016. The most frequent treatment-related adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.5%), and nausea (11.4%). Grades 3 to 4 treatment-related adverse events occurred in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite. The confirmed objective response rate by independent central review was 18.2% (95% CI, 8.2% to 32.7%; five complete responses and three partial responses). The median duration of response was not reached (95% CI, 12.1 weeks to not estimable), and responses were ongoing in six patients (75.0%), including four of five complete responses. Seven of eight responding patients had PD-L1-positive tumors. The median progression-free survival was 11.6 weeks (95% CI, 6.1 to 17.4 weeks); the median OS was 13.7 months (95% CI, 8.5 months to not estimable), with a 12-month OS rate of 54.3% (95% CI, 37.9% to 68.1%). Conclusion Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic UC

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1). We report ≥2-year follow-up data for avelumab treatment and exploratory subgroup analyses in patients with urothelial carcinoma. METHODS: Patients with previously treated advanced/metastatic urothelial carcinoma, pooled from two cohorts of the phase Ib JAVELIN Solid Tumor trial, received avelumab 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity or withdrawal. End points included best overall response and progression-free survival (PFS) per RECIST V.1.1, overall survival (OS) and safety. Post hoc analyses included objective response rates (ORRs) in subgroups defined by established high-risk/poor-prognosis characteristics and association between time to response and outcome. RESULTS: 249 patients received avelumab; efficacy was assessed in 242 postplatinum patients. Median follow-up was 31.9 months (range 24-43), and median treatment duration was 2.8 months (range 0.5-42.8). The confirmed ORR was 16.5% (95% CI 12.1% to 21.8%; complete response in 4.1% and partial response in 12.4%). Median duration of response was 20.5 months (95% CI 9.7 months to not estimable). Median PFS was 1.6 months (95% CI 1.4 to 2.7 months) and the 12-month PFS rate was 16.8% (95% CI 11.9% to 22.4%). Median OS was 7.0 months (95% CI 5.9 to 8.5 months) and the 24-month OS rate was 20.1% (95% CI 15.2% to 25.4%). In post hoc exploratory analyses, avelumab showed antitumor activity in high-risk subgroups, including elderly patients and those with renal insufficiency or upper tract disease; ORRs were numerically lower in patients with liver metastases or low albumin levels. Objective response achieved by 3 months versus later was associated with longer OS (median not reached (95% CI 18.9 months to not estimable) vs 7.1 months (95% CI 5.2 to 9.0 months)). Safety findings were consistent with previously reported 6-month analyses. CONCLUSIONS: After ≥2 years of follow-up, avelumab showed prolonged efficacy and acceptable safety in patients with platinum-treated advanced/metastatic urothelial carcinoma, including high-risk subgroups. Survival appeared longer in patients who responded within 3 months. Long-term safety findings were consistent with earlier reports with avelumab treatment in this patient population

Predicting Cancer Immunotherapy Response From Gut Microbiomes Using Machine Learning Models

Cancer immunotherapy has significantly improved patient survival. Yet, half of patients do not respond to immunotherapy. Gut microbiomes have been linked to clinical responsiveness of melanoma patients on immunotherapies; however, different taxa have been associated with response status with implicated taxa inconsistent between studies. We used a tumor-agnostic approach to find common gut microbiome features of response among immunotherapy patients with different advanced stage cancers. A combined meta-analysis of 16S rRNA gene sequencing data from our mixed tumor cohort and three published immunotherapy gut microbiome datasets from different melanoma patient cohorts found certain gut bacterial taxa correlated with immunotherapy response status regardless of tumor type. Using multivariate selbal analysis, we identified two separate groups of bacterial genera associated with responders versus non-responders. Statistical models of gut microbiome community features showed robust prediction accuracy of immunotherapy response in amplicon sequencing datasets and in cross-sequencing platform validation with shotgun metagenomic datasets. Results suggest baseline gut microbiome features may be predictive of clinical outcomes in oncology patients on immunotherapies, and some of these features may be generalizable across different tumor types, patient cohorts, and sequencing platforms. Findings demonstrate how machine learning models can reveal microbiome-immunotherapy interactions that may ultimately improve cancer patient outcomes